mivavotinib

also known as TAK-659 · CB-659 · MIVAVOTINIB CITRATE · TAK-659 FREE BASE · TAK-659F

Developed for: lymphoma · non-Hodgkin lymphoma · acute myeloid leukemia · diffuse large B-cell lymphoma · diffuse large B-cell lymphoma activated B-cell type · high grade malignant neoplasm · adenocarcinoma · diffuse large B-cell lymphoma germinal center B-cell type
+8 more
· follicular lymphoma · head and neck squamous cell carcinoma · high grade B-cell lymphoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · non-small cell lung carcinoma · ovarian carcinoma · T-cell/histiocyte rich large B cell lymphoma · triple-negative breast carcinoma
Investigated by: Calithera Biosciences, Inc · Millennium Pharmaceuticals, Inc. · National Cancer Institute (NCI) · H Scott Boswell · M.D. Anderson Cancer Center · Nektar Therapeutics
+2 more
· Northwestern University · Takeda

Trials 15 · a red edge is where a trial was stopped

today NCT05319028 · Ph 2 NCT04079738 · Ph 1/2 NCT03772288 · Ph 1 NCT03742258 · Ph 1 NCT03756818 · Ph 1 NCT03338881 · Ph 1 NCT03359733 · Ph 1 NCT03357627 · Ph 1 NCT03123393 · Ph 2 NCT03238651 · Ph 1 NCT02954406 · Ph 1 NCT02834247 · Ph 1 NCT02551055 · Ph 1 NCT02323113 · Ph 1/2 NCT02000934 · Ph 1

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 111 trials
Phase 1	NCT03772288	Apr 2019 → Nov 2021	non-Hodgkin lymphoma	Calithera Biosciences, Inc	Withdrawn	No outcome recorded
Phase 1	NCT03742258	Mar 2019 → Mar 2021	T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, high grade B-cell lymphoma +1	Northwestern University	Completed	No outcome recorded
Phase 1	NCT03756818	Mar 2019 → Feb 2023	ovarian carcinoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1	NCT03338881	May 2018 → May 2019	high grade malignant neoplasm, lymphoma	Calithera Biosciences, Inc	Withdrawn	No outcome recorded
Phase 1	NCT03359733	Feb 2018 → Jan 2019	high grade malignant neoplasm, lymphoma	Calithera Biosciences, Inc	Withdrawn	No outcome recorded
Phase 1	NCT03357627	Feb 2018 → Aug 2021	diffuse large B-cell lymphoma, follicular lymphoma	Calithera Biosciences, Inc	Completed	No outcome recorded
Phase 1	NCT03238651	Aug 2017 → Aug 2020	non-Hodgkin lymphoma	Calithera Biosciences, Inc	Terminated	No outcome recorded
Phase 1	NCT02954406	Mar 2017 → Jul 2020	non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 1	NCT02834247	Aug 2016 → Nov 2018	head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma	Calithera Biosciences, Inc	Terminated	No outcome recorded
Phase 1	NCT02551055	Oct 2015 → Feb 2017	adenocarcinoma	Millennium Pharmaceuticals, Inc.	Terminated	No outcome recorded
Phase 1	NCT02000934	Dec 2013 → Jun 2021	lymphoma	Calithera Biosciences, Inc	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT04079738	Sep 2019 → Sep 2021	acute myeloid leukemia	H Scott Boswell	Terminated	No outcome recorded
Phase 1/2	NCT02323113	Mar 2015 → Jun 2018	acute myeloid leukemia	Calithera Biosciences, Inc	Terminated	No outcome recorded
Phase 22 trials
Phase 2	NCT05319028	Jun 2022 → Feb 2023	diffuse large B-cell lymphoma activated B-cell type	Calithera Biosciences, Inc	Terminated	No outcome recorded
Phase 2	NCT03123393	Oct 2017 → Dec 2019	diffuse large B-cell lymphoma	Calithera Biosciences, Inc	Terminated	No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

Field	Value	Cited text
Known as	mivavotinib	“Mivavotinib (TAK-659/CB-659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti-PD-1 therapy in...” PMID 38501219 ↗ Mar 2024 4 “Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3).” PMID 36226495 ↗ Mar 2023 “updated data with mivavotinib (TAK-659/CB-659).” PMID 36702329 ↗ Jan 2023 NCT03756818 ↗ NCT05319028 ↗
Known as	CB-659	“Mivavotinib (TAK-659/CB-659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti-PD-1 therapy in...” PMID 38501219 ↗ Mar 2024 1 “updated data with mivavotinib (TAK-659/CB-659).” PMID 36702329 ↗ Jan 2023
Known as	MIVAVOTINIB CITRATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3979920 ↗
Known as	TAK-659	“Mivavotinib (TAK-659/CB-659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti-PD-1 therapy in...” PMID 38501219 ↗ Mar 2024 13 “Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3).” PMID 36226495 ↗ Mar 2023 “I. To define the maximum tolerated doses (MTD) of mivavotinib (TAK-659) and paclitaxel.” NCT03756818 ↗ NCT03359733 ↗ NCT02000934 ↗ NCT03742258 ↗ NCT03357627 ↗ NCT02551055 ↗ NCT03238651 ↗ NCT02954406 ↗ NCT03772288 ↗ NCT03338881 ↗ NCT04079738 ↗ NCT03123393 ↗
Known as	TAK-659 FREE BASE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3979920 ↗
Known as	TAK-659F	ChEMBL registry synonym — accepted as the source's own label CHEMBL3979920 ↗
Action	Inhibit	“TAK-659 is an investigational, dual SYK/FLT3 inhibitor” PMID 32327472 ↗ Apr 2020
Modality	Small molecule	— CHEMBL3979920 ↗
Route	Oral	“Patients received continuous, once-daily oral TAK-659” PMID 32327472 ↗ Apr 2020
Target	FLT3	“TAK-659 is an investigational, dual SYK/FLT3 inhibitor” PMID 32327472 ↗ Apr 2020
Target	SYK	“TAK-659 is an investigational, dual SYK/FLT3 inhibitor” PMID 32327472 ↗ Apr 2020